Clinical Characteristics and Outcome of 48 Patients (relapses and deaths)
| Parameter . | No. . | % . | Homozygous p16 Deletion Present . | Deaths . | Relapse* . | |||
|---|---|---|---|---|---|---|---|---|
| . | . | . | No. . | % . | No. . | % . | No. . | % . |
| All patients | 48 | 100 | 9 | 18.3 | 10 | 20.8 | 14/47 | 29.8 |
| Males | 34 | 70.8 | 8 | 23.5 | 6 | 17.7 | 10/33 | 30.3 |
| Females | 14 | 29.2 | 1 | 7.1 | 4 | 28.6 | 4/14 | 28.6 |
| Age < 1 or ≥ 10 yr | 9 | 18.8 | 1 | 11.1 | 4 | 44.4 | 4/9 | 44.4 |
| 1 ≤ age < 10 yr | 39 | 81.3 | 8 | 20.5 | 6 | 15.4 | 10/38 | 26.3 |
| WBC ≥ 50,000 | 17 | 35.4 | 6 | 35.3 | 6 | 35.3 | 8/17 | 47.1 |
| WBC < 50,000 | 31 | 64.6 | 3 | 9.68 | 4 | 12.9 | 6/30 | 20.0 |
| T-ALL | 8 | 16.7 | 5 | 62.5 | 2 | 25.0 | 3/8 | 37.5 |
| Precursor-B-ALL | 40 | 83.3 | 4 | 10 | 8 | 20.0 | 11/39 | 28.2 |
| High risk | 23 | 47.9 | 8 | 34.8 | 8 | 34.8 | 10/23 | 43.5 |
| Standard risk | 25 | 52.1 | 1 | 4.0 | 2 | 8.0 | 4/24 | 16.7 |
| Homozygous p16 deletion present | 9 | 18.8 | — | 5 | 55.6 | 6/9 | 66.7 | |
| Homozygous p16 deletion absent | 39 | 81.3 | — | 5 | 12.8 | 8/38 | 12.8 | |
| Parameter . | No. . | % . | Homozygous p16 Deletion Present . | Deaths . | Relapse* . | |||
|---|---|---|---|---|---|---|---|---|
| . | . | . | No. . | % . | No. . | % . | No. . | % . |
| All patients | 48 | 100 | 9 | 18.3 | 10 | 20.8 | 14/47 | 29.8 |
| Males | 34 | 70.8 | 8 | 23.5 | 6 | 17.7 | 10/33 | 30.3 |
| Females | 14 | 29.2 | 1 | 7.1 | 4 | 28.6 | 4/14 | 28.6 |
| Age < 1 or ≥ 10 yr | 9 | 18.8 | 1 | 11.1 | 4 | 44.4 | 4/9 | 44.4 |
| 1 ≤ age < 10 yr | 39 | 81.3 | 8 | 20.5 | 6 | 15.4 | 10/38 | 26.3 |
| WBC ≥ 50,000 | 17 | 35.4 | 6 | 35.3 | 6 | 35.3 | 8/17 | 47.1 |
| WBC < 50,000 | 31 | 64.6 | 3 | 9.68 | 4 | 12.9 | 6/30 | 20.0 |
| T-ALL | 8 | 16.7 | 5 | 62.5 | 2 | 25.0 | 3/8 | 37.5 |
| Precursor-B-ALL | 40 | 83.3 | 4 | 10 | 8 | 20.0 | 11/39 | 28.2 |
| High risk | 23 | 47.9 | 8 | 34.8 | 8 | 34.8 | 10/23 | 43.5 |
| Standard risk | 25 | 52.1 | 1 | 4.0 | 2 | 8.0 | 4/24 | 16.7 |
| Homozygous p16 deletion present | 9 | 18.8 | — | 5 | 55.6 | 6/9 | 66.7 | |
| Homozygous p16 deletion absent | 39 | 81.3 | — | 5 | 12.8 | 8/38 | 12.8 | |
One patient was excluded from the analysis of time to first relapse.